LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 148

Search options

  1. Article: A quick algorithmic review on management of viral infectious diseases in pediatric solid organ transplant recipients.

    Moghadamnia, Marjan / Eshaghi, Hamid / Alimadadi, Hosein / Dashti-Khavidaki, Simin

    Frontiers in pediatrics

    2023  Volume 11, Page(s) 1252495

    Abstract: Pediatric solid organ transplant is a life-saving procedure for children with end-stage organ failure. Viral infections are a common complication following pediatric solid organ transplantation (SOT), which can lead to increased morbidity and mortality. ... ...

    Abstract Pediatric solid organ transplant is a life-saving procedure for children with end-stage organ failure. Viral infections are a common complication following pediatric solid organ transplantation (SOT), which can lead to increased morbidity and mortality. Pediatric solid organ transplant recipients are at an increased risk of viral infections due to their immunosuppressed state. The most commonly encountered viruses include cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus (HSV), varicella-zoster virus (VZV), adenoviruses, and BK polyomavirus. Prevention strategies include vaccination prior to transplantation, post-transplant prophylaxis with antiviral agents, and preemptive therapy. Treatment options vary depending on the virus and may include antiviral therapy and sometimes immunosuppression modification. This review provides a Quick Algorithmic overview of prevention and treatment strategies for viral infectious diseases in pediatric solid organ transplant recipient.
    Language English
    Publishing date 2023-09-04
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2711999-3
    ISSN 2296-2360
    ISSN 2296-2360
    DOI 10.3389/fped.2023.1252495
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Considerations for Statin Therapy in Patients with COVID-19.

    Dashti-Khavidaki, Simin / Khalili, Hossein

    Pharmacotherapy

    2020  Volume 40, Issue 5, Page(s) 484–486

    MeSH term(s) Animals ; Antiviral Agents/therapeutic use ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/drug therapy ; Drug Interactions ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/drug therapy ; Respiratory Distress Syndrome/drug therapy ; Respiratory Distress Syndrome/virology ; SARS-CoV-2 ; COVID-19 Drug Treatment
    Chemical Substances Antiviral Agents ; Hydroxymethylglutaryl-CoA Reductase Inhibitors
    Keywords covid19
    Language English
    Publishing date 2020-05-04
    Publishing country United States
    Document type Letter
    ZDB-ID 603158-4
    ISSN 1875-9114 ; 0277-0008
    ISSN (online) 1875-9114
    ISSN 0277-0008
    DOI 10.1002/phar.2397
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Donor's Versus Recipient's Demographic Data for Estimating Kidney Function in Kidney Transplant Recipients.

    Nabiee, Morteza / Dashti-Khavidaki, Simin

    Journal of research in pharmacy practice

    2019  Volume 8, Issue 3, Page(s) 179–180

    Language English
    Publishing date 2019-10-16
    Publishing country India
    Document type Journal Article
    ZDB-ID 2734861-1
    ISSN 2279-042X ; 2319-9644
    ISSN (online) 2279-042X
    ISSN 2319-9644
    DOI 10.4103/jrpp.JRPP_19_23
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: The need for an integrated pharmacological response to the treatment of HIV/AIDS and depression.

    Borran, Mina / Dashti-Khavidaki, Simin / Khalili, Hossein

    Expert opinion on pharmacotherapy

    2021  Volume 22, Issue 9, Page(s) 1179–1192

    Abstract: Introduction: ...

    Abstract Introduction:
    MeSH term(s) Acquired Immunodeficiency Syndrome ; Comorbidity ; Depression/drug therapy ; HIV Infections/complications ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; Humans ; Medication Adherence
    Language English
    Publishing date 2021-02-13
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2021.1882419
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Management of drug-induced neutropenia, thrombocytopenia, and anaemia after solid organ transplantation: A comprehensive review.

    Baradaran, Hananeh / Hashem Zadeh, Arezou / Dashti-Khavidaki, Simin / Laki, Bahareh

    Journal of clinical pharmacy and therapeutics

    2022  

    Abstract: What is known and objective: Advances in the development of more effective immunosuppressive drugs have increased graft survival and drug induced adverse effects. Haematological complications including neutropenia, thrombocytopenia, and anaemia are ... ...

    Abstract What is known and objective: Advances in the development of more effective immunosuppressive drugs have increased graft survival and drug induced adverse effects. Haematological complications including neutropenia, thrombocytopenia, and anaemia are common side effects that affect the grafts' and patients' outcomes. Several studies have stated the important role of various medications in haematological complications after transplantation. They have reported the incidence and different mechanisms of drug induced cytopenia, as well as an overview of possible treatment modalities. However, there is no comprehensive protocol for the management of these complications following transplantation. This narrative review was performed to develop a comprehensive practical approach for management of drug induced haematological complications following solid organ transplantation.
    Method: PubMed, Embase, Cochrane library, Web of Science, and Google scholar databases were searched without time limitations until March, 2021. In addition, some valid drug information data bases (Uptodate and Micromedex) were searched for detailed information until October, 2021.
    Results and discussion: Several immunosuppressive and antimicrobial medications may induce neutropenia, thrombocytopenia or anaemia following transplantation. Most of these agents cause dose-related cytopenia, which resolves with dose reduction or drug withdrawal. However, any change in medications may result in negative consequences such as severe infections, bleeding, cardiovascular complications, acute allograft rejection, and graft or patient loss. Thus, cautious evaluation of the patient's condition and the pharmacological properties of the culprit medication are required.
    What is new and conclusion: Three algorithms are presented to guide healthcare providers in the stepwise management of drug-induced neutropenia, thrombocytopenia, and anaemia after solid organ transplantation.
    Language English
    Publishing date 2022-10-17
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 639006-7
    ISSN 1365-2710 ; 0269-4727
    ISSN (online) 1365-2710
    ISSN 0269-4727
    DOI 10.1111/jcpt.13775
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Current status of glucocorticoid usage in solid organ transplantation.

    Dashti-Khavidaki, Simin / Saidi, Reza / Lu, Hong

    World journal of transplantation

    2021  Volume 11, Issue 11, Page(s) 443–465

    Abstract: Glucocorticoids (GCs) have been the mainstay of immunosuppressive therapy in solid organ transplantation (SOT) for decades, due to their potent effects on innate immunity and tissue protective effects. However, some SOT centers are reluctant to ... ...

    Abstract Glucocorticoids (GCs) have been the mainstay of immunosuppressive therapy in solid organ transplantation (SOT) for decades, due to their potent effects on innate immunity and tissue protective effects. However, some SOT centers are reluctant to administer GCs long-term because of the various related side effects. This review summarizes the advantages and disadvantages of GCs in SOT. PubMed and Scopus databases were searched from 2011 to April 2021 using search syntaxes covering "transplantation" and "glucocorticoids". GCs are used in transplant recipients, transplant donors, and organ perfusate solution to improve transplant outcomes. In SOT recipients, GCs are administered as induction and maintenance immunosuppressive therapy. GCs are also the cornerstone to treat acute antibody- and T-cell-mediated rejections. Addition of GCs to organ perfusate solution and pretreatment of transplant donors with GCs are recommended by some guidelines and protocols, to reduce ischemia-reperfusion injury peri-transplant. GCs with low bioavailability and high potency for GC receptors, such as budesonide, nanoparticle-mediated targeted delivery of GCs to specific organs, and combination use of dexamethasone with inducers of immune-regulatory cells, are new methods of GC application in SOT patients to reduce side effects or induce immune-tolerance instead of immunosuppression. Various side effects involving different non-targeted organs/tissues, such as bone, cardiovascular, neuromuscular, skin and gastrointestinal tract, have been noted for GCs. There are also potential drug-drug interactions for GCs in SOT patients.
    Language English
    Publishing date 2021-11-09
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2220-3230
    ISSN 2220-3230
    DOI 10.5500/wjt.v11.i11.443
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Considerations for Statin Therapy in Patients with COVID‐19

    Dashti‐Khavidaki, Simin / Khalili, Hossein

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    2020  Volume 40, Issue 5, Page(s) 484–486

    Keywords Pharmacology (medical) ; covid19
    Language English
    Publisher Wiley
    Publishing country us
    Document type Article ; Online
    ZDB-ID 603158-4
    ISSN 1875-9114 ; 0277-0008
    ISSN (online) 1875-9114
    ISSN 0277-0008
    DOI 10.1002/phar.2397
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article ; Online: Dose discordance of direct acting oral anticoagulants using different equations for estimating GFR: a literature review.

    Nabiee, Morteza / Dashti-Khavidaki, Simin / Khajeh, Behrouz

    Expert review of clinical pharmacology

    2020  Volume 13, Issue 8, Page(s) 857–863

    Abstract: Introduction: Direct oral anticoagulants (DOACs) are widely prescribed nowadays. Available DOACs are renally eliminated to some extent and need dose adjustment in patients with kidney dysfunction. Cockcroft-Gault (CG) formula has been used to estimate ... ...

    Abstract Introduction: Direct oral anticoagulants (DOACs) are widely prescribed nowadays. Available DOACs are renally eliminated to some extent and need dose adjustment in patients with kidney dysfunction. Cockcroft-Gault (CG) formula has been used to estimate creatinine clearance in DOACs trials. Nowadays, Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) are preferred equations for estimating glomerular filtration rate (GFR). We reviewed studies that simulated DOACs dosing in patients with atrial fibrillation by MDRD, CKD-EPI, and CG.
    Areas covered: DOACs dose discordance varies from 28.8% underdosing to 59.2% overdosing when MDRD or CKD-EPI equations are substituted for CG. MDRD and CKD-EPI overestimate the GFR in lower thresholds of kidney function especially in elderly and females and result in overestimation of DOACs dosing or misclassifying the patients to be eligible for receiving DOACs when they are contraindicated. Compared with CG, MDRD and CKD-EPI underestimate the level of kidney function in higher GFR extremes and in these patients suggest DOACs when they are not recommended or suggest lower doses.
    Expert opinion: Until running large clinical studies on efficacy/safety of DOACs dosing using MDRD or CKD-EPI equations, use of CG method for DOACs dosing is recommended in real practice.
    MeSH term(s) Administration, Oral ; Aged ; Atrial Fibrillation/drug therapy ; Dose-Response Relationship, Drug ; Drug Dosage Calculations ; Factor Xa Inhibitors/administration & dosage ; Factor Xa Inhibitors/pharmacokinetics ; Female ; Glomerular Filtration Rate/physiology ; Humans ; Kidney Diseases/physiopathology ; Kidney Function Tests ; Male
    Chemical Substances Factor Xa Inhibitors
    Language English
    Publishing date 2020-07-27
    Publishing country England
    Document type Comparative Study ; Journal Article ; Review
    ISSN 1751-2441
    ISSN (online) 1751-2441
    DOI 10.1080/17512433.2020.1798759
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Pharmacotherapy Considerations in CKD Patients With COVID-19, A Narrative Review.

    Dashti-Khavidaki, Simin / Khalili, Hossein / Nourian, Anahid

    Iranian journal of kidney diseases

    2020  Volume 14, Issue 4, Page(s) 247–255

    Abstract: Treatment of coronavirus disease 2019 (COVID-19) among patients with CKD requires special pharmacotherapy considerations that are reviewed here. Literature review was done for several pharmacotherapy aspects in CKD patients including selection and ... ...

    Abstract Treatment of coronavirus disease 2019 (COVID-19) among patients with CKD requires special pharmacotherapy considerations that are reviewed here. Literature review was done for several pharmacotherapy aspects in CKD patients including selection and modification of COVID-19 treatment, drug interactions, nephrotoxicity of drugs that are used for treatment of COVID-19 and potential risks/benefits of routine medications of CKD patients during COVID-19 pandemic. CKD patients should be treated according to local or national COVID-19 protocols as other patients. But, there is no data on using remdesivir in patients with severe CKD. Oseltamivir and ribavirin require dose modification in patients with moderate to severe CKD. Nephrolithiasis, CKD, and acute interstitial nephritis have been reported with protease inhibitors. Acute kidney injury has been reported with remdesivir in patients with severe COVID-19. Pharmacokinetic-enhanced protease inhibitors increase the concentration of some drugs such as statins, cinacalcet, steroids, calcineurin inhibitors (CNIs). Some hypothetical benefits and harms have been suggested for statins and renin-angiotensinaldosterone system inhibitors in COVID-19 patients. Continuing guideline-directed administration of these drugs is recommended. Among different immunomodulating/immunosuppressive drugs, hydroxychloroquine and CNIs are the safest ones during COVID-19. Antimetabolites are suggested to be withheld during moderate to severe COVID-19. Fluid therapy and anticoagulant prophylaxis/ treatment need special attention in CKD patients with COVID-19. CKD patients with COVID-19 are treated as other patients, with some dose modifications if needed. Be mindful for management of drug interactions as well as modification of immunosuppressive drugs in patients with moderate to severe COVID-19.
    MeSH term(s) Betacoronavirus/isolation & purification ; Comorbidity ; Coronavirus Infections/classification ; Coronavirus Infections/complications ; Coronavirus Infections/drug therapy ; Coronavirus Infections/epidemiology ; Drug-Related Side Effects and Adverse Reactions/classification ; Drug-Related Side Effects and Adverse Reactions/etiology ; Drug-Related Side Effects and Adverse Reactions/prevention & control ; Humans ; Pandemics ; Patient Selection ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/epidemiology ; Renal Insufficiency, Chronic/drug therapy ; Renal Insufficiency, Chronic/epidemiology ; Risk Assessment
    Keywords covid19
    Language English
    Publishing date 2020-06-20
    Publishing country Iran
    Document type Journal Article ; Review
    ZDB-ID 2388271-2
    ISSN 1735-8604 ; 1735-8582
    ISSN (online) 1735-8604
    ISSN 1735-8582
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top